STK11 pathway in vitro validation

The associated publication reports proteogenomic analysis of non-small cell lung cancer (NSCLC), where we identified molecular subtypes with distinct immune evasion mechanisms and therapeutic targets, and validated our classification method in separate clinical cohorts. The in-depth proteomic analysis pointed to a potential role of STK11 inactivation in liver-specific signaling and subsequent cancer growth and immune evasion mechanisms. This protocol describes in vitro validation of the downstream effects of STK11-AMPK signaling on HNF1A and FGL1 in a liver and two lung cancer cell lines.